Campillo J A, Lanao J M, Dominguez-Gil A, Rubio F, Martin A
Eur J Clin Pharmacol. 1980 Oct;18(4):347-50. doi: 10.1007/BF00561393.
The pharmacokinetics of Dibekacin were studied in 10 patients with terminal renal impairment (creatinine clearance < 5 ml/min) undergoing haemodialysis sessions lasting 4 h. The dialyzers were either the Gambro Lundia Major 13.5 or the Ultra Flo II 1.4., and the patients were divided into two groups according to the dialyzer used. Blood flow varied between 250 and 280 ml/min and dialyzate flow between 450 and 600 ml/min. All patients received a single i. v. dose of Dibekacin 1.5 mg/kg at the beginning of the dialysis session. The concentration of the antibiotic at the input and the output of the dialyzer were determine microbiologically by a plate diffusion method using B. subtilis as the test organism. The intravenously administered antibiotic followed an open two-compartment kinetic model. The type of dialyzer used did not influence the dialysis of Dibekacin. Haemodialysis significantly increased the elimination rate of the antibiotic with respect to the interdialysis periods. The plasma half-life in the slow disposition phase fell from 30 h in the interdialysis period to 4.0 h during dialysis sessions. From the calculated pharmacokinetic parameters, a dosage regimen for this kind of patient is proposed.
对10例终末期肾功能损害（肌酐清除率<5ml/min）且正在进行持续4小时血液透析的患者，研究了地贝卡星的药代动力学。透析器为金宝Lundia Major 13.5或超流量II 1.4，根据所使用的透析器将患者分为两组。血流量在250至280ml/min之间，透析液流量在450至600ml/min之间。所有患者在透析开始时静脉注射单剂量1.5mg/kg的地贝卡星。采用平板扩散法，以枯草芽孢杆菌作为测试菌，微生物学测定透析器进出口处抗生素的浓度。静脉注射的抗生素遵循开放二室动力学模型。所使用的透析器类型不影响地贝卡星的透析。与透析间期相比，血液透析显著提高了抗生素的清除率。慢处置期的血浆半衰期从透析间期的30小时降至透析期间的4.0小时。根据计算得到的药代动力学参数，提出了此类患者的给药方案。
